Register for our free email digests:
3SBio Inc.
www.3sbio.com
Latest From 3SBio Inc.
Finance Watch: Kymera Will Start Protein Degrader Clinical Trials With $102m VC Round
Private Company Edition: Kymera said it will take up to three programs into the clinic by next year. Also, three new life science funds recently launched, including a Gates Foundation-backed accelerator for COVID-19 treatments, and Cell Medica reemerges as Kuur with new funding for CAR-NKT therapies.
Venture Funding Deals: Tenaya's $92m, Nuvation's $275m Lead October Rounds
Former Medivation CEO David Hung launched stealthy oncology start-up Nuvation with $275m in series A venture capital, while Tenaya's series B brought in $92m for small molecules as well as cell and gene therapies to treat cardiovascular diseases.
Finance Watch: BIO Says Proposed Foreign Investment Regulations Will Lower Investment In US Biotech
Private Company Edition: BIO comments suggest definitions of personal data expand the scope of foreign investments in biotech companies that must be reviewed by the Committee on Foreign Investment in the United States (CFIUS). Also, NeuroRx’s $95m deal leads recent private financings.
Chinese Biosimilar Boom Is Heralded By First Approval
Approval of China's first rituximab biosimilar under new pathway gives developers much-needed boost and an opening to the international market for made-in-China biosimilars helped by favorable regulatory policy changes at home.
Company Information
- Industry
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
-
Pharmaceuticals
- Generic Drugs
- Vaccines
- Therapeutic Areas
- Cancer
- Infectious & Viral Diseases
- Inflammation
- Renal System
- Alias(es)
- Shenyang Sunshine Pharmaceutical Co. Ltd.
- Ownership
- Private
- Headquarters
-
Worldwide
-
Asia
-
China
-
China
-
Asia
- Parent & Subsidiaries
- 3SBio Inc.
- Senior Management
-
Jing Lou, PhD, Chmn., Pres. & CEO
Bo Tan, EVP, CFO
Zhenping Zhu, PhD, Pres., R&D & CSO - Contact Info
-
3SBio Inc.
Phone: (86) 24 2581 1820
No. 3 A1, Rd. 10
Shenyang, 110027
China
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice